What they were paid
Merck Director Compensation Table · all 4 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $120,000 | — | — | $220,000 | $340,000 |
| FY2024 | $120,000 | $0 | $0 | $220,000 | $340,000 |
| FY2023 | $122,361 | $0 | $0 | $220,000 | $342,361 |
| FY2022 | $130,000 | $0 | $0 | $220,000 | $350,000 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Merck & Co., Inc. DEF 14A filed April 8, 2026, accession 0001193125-26-147704, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Merck pays directors a $120,000 cash retainer and $220,000 in Deferred Stock Units (phantom shares).
Committees
FY2025 · as the proxy prints themCompensation · Research
The rest of the Merck board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Christine E. Seidman, M.D | Independent Director | $385,000 |
| Douglas M. Baker Jr | Independent Director | $350,000 |
| Inge G. Thulin | Independent Director | $340,000 |
| Kathy J. Warden | Independent Director | $340,000 |
| Pamela J. Craig | Independent Director | $405,000 |
| Patricia F. Russo | Independent Director | $365,000 |
| Paul B. Rothman, M.D | Independent Director | $405,000 |
| Risa J. Lavizzo-Mourey, M.D | Independent Director | $340,000 |
| Robert M. Davis | Chair of the Board | $0 |
| Stephen L. Mayo, Ph.D | Independent Director | $350,000 |
| Surendralal L. Karsanbhai | Independent Director | $405,000 |
| Thomas H. Glocer | Lead Independent Director | $415,000 |
The full Merck compensation record
free company briefThis page is one director within Merck's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat